KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cvs Health (CVS) Gains from Investment Securities (2016 - 2025)

Cvs Health (CVS) has disclosed Gains from Investment Securities for 12 consecutive years, with $2.0 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 637.59% year-over-year to $2.0 billion, compared with a TTM value of $2.3 billion through Dec 2025, up 33.71%, and an annual FY2025 reading of $2.2 billion, up 27.19% over the prior year.
  • Gains from Investment Securities was $2.0 billion for Q4 2025 at Cvs Health, up from -$718.0 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.8 billion in Q4 2022 and bottomed at -$718.0 million in Q3 2025.
  • Average Gains from Investment Securities over 5 years is $415.1 million, with a median of $79.5 million recorded in 2022.
  • The sharpest move saw Gains from Investment Securities surged 53885.71% in 2022, then plummeted 202.57% in 2025.
  • Year by year, Gains from Investment Securities stood at $7.0 million in 2021, then soared by 53885.71% to $3.8 billion in 2022, then tumbled by 94.07% to $224.0 million in 2023, then rose by 22.32% to $274.0 million in 2024, then skyrocketed by 637.59% to $2.0 billion in 2025.
  • Business Quant data shows Gains from Investment Securities for CVS at $2.0 billion in Q4 2025, -$718.0 million in Q3 2025, and $274.0 million in Q4 2024.